{"id":499861,"date":"2020-08-01T00:00:00","date_gmt":"2020-07-30T20:06:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=499861"},"modified":"2020-07-30T20:06:01","modified_gmt":"2020-07-30T20:06:01","slug":"acromegaly-pipeline-insights-and-key-players-2020","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/acromegaly-pipeline-insights-and-key-players-2020_499861.html","title":{"rendered":"Acromegaly Pipeline Insights and Key Players – 2020"},"content":{"rendered":"
\"Acromegaly<\/a><\/p>\n
\n
DelveInsight Business Research LLP <\/div>\n<\/div>\n<\/div>\n
Acromegaly Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Acromegaly market. A detailed picture of the Acromegaly pipeline landscape is provided, which includes the disease overview and Acromegaly treatment guidelines.<\/p>\n<\/div>\n

Acromegaly is a rare and chronic disorder characterized by excess growth hormone secretion and elevated insulin-like growth factor-1 levels, most often caused by a pituitary Adenoma.<\/p>\n

 <\/p>\n

Acromegaly Emerging Drugs<\/a><\/p>\n

 <\/p>\n

    \n
  1. IONIS-GHR-LRx: Ionis Pharmaceuticals<\/li>\n
  2. Mycapssa (Octreotide Capsules): Chiasma Pharma<\/li>\n
  3. ATL1103: Antisense Therapeutics<\/li>\n
  4. CAM2029: Camurus<\/li>\n
  5. GT-02037 (G-SRIF): GlyTech<\/li>\n
  6. Veldoreotide (COR-005, DG3173): Strongbridge Biopharma<\/li>\n
  7. Paltusotine (CRN00808): Crinetics Pharmaceuticals<\/li>\n
  8. MTD201: Midatech<\/li>\n
  9. Lanreotide PRF: Ipsen<\/li>\n<\/ol>\n

    Scope of the Report<\/span><\/strong><\/p>\n